KDR and neoplasm: Examples include Sorafenib, which targets multiple kinases involved in tumor growth and angiogenesis [203]; Lenvatinib, which inhibits multiple receptors like VEGFR and FGFR to hinder tumor angiogenesis and proliferation [204]; and Erlotinib, which specifically targets the epidermal growth factor receptor (EGFR) pathway [205].